HFS
PCRX icon

Hantz Financial Services’s Pacira BioSciences PCRX Stock Holding History

Hantz Financial Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
1,123
+42
+4% +$993 ﹤0.01% 1845
2026
Q1 		$24K Sell
1,081
-1,492
-58% -$33.2K ﹤0.01% 1810
2025
Q4 		$67K Buy
2,573
+1,441
+127% +$34.3K ﹤0.01% 1305
2025
Q3 		$29K Buy
1,132
+721
+175% +$17.7K ﹤0.01% 1437
2025
Q2 		$10K Buy
411
+353
+609% +$8.9K ﹤0.01% 1517
2025
Q1 		$1K Buy
+58
New +$1.39K ﹤0.01% 1579

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hantz Financial Services's PCRX Position: Q2 2026 in Review

Hantz Financial Services increased its Pacira BioSciences (PCRX) stake by 3.9% in Q2 2026, buying an estimated $993 and bringing the position to 1,123 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Hantz Financial Services first reported a position in PCRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $67K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Hantz Financial Services held 1,123 shares of Pacira BioSciences worth $28K as of Q2 2026.
  • Hantz Financial Services bought 42 Pacira BioSciences shares in Q2 2026, an estimated $993.
  • Pacira BioSciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1845 holding.
  • Hantz Financial Services first reported a position in Pacira BioSciences in Q1 2025 and has held it in 6 quarters since.
  • Hantz Financial Services's Pacira BioSciences position peaked at $67K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.